President and Chief Executive Officer · Y-mAbs Therapeutics, Inc. (YMAB)

Michael Rossi

A named executive officer of Y-mAbs Therapeutics in every fiscal year CompBrief holds from FY2023 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2024

$4,557,590

FY2023: $3,110,553

1st of 3 named executive officers at Y-mAbs Therapeutics by FY2024 total.

3 named officers on file for Y-mAbs Therapeutics, FY2024

See an example →

What this number hides

The filing gives the total. Y-mAbs Therapeutics’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Compensation figures as of the proxy filed May 30, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-07.

Free

Get Michael Rossi’s full pay file as a PDF — free

More than this page: up to 10 years of Michael’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Michael Rossi and every company like it: Velarion Intel, free for 3 days, no card →

Michael Rossi compensation by year

Y-mAbs Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Y-mAbs Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024
Salary$109,582$705,600
Bonus$371,623$0
Stock awards$0$1,170,732
Option awards$2,629,348$2,288,662
Non-equity incentive$0$392,596
Pension and deferred compensation$0$0
All other$0$0
Total$3,110,553$4,557,590

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Y-mAbs Therapeutics, Inc. DEF 14A filed May 30, 2025, accession 0001558370-25-008299, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Y-mAbs Therapeutics, Inc. filed document, accession 0001558370-25-008299. Every figure is read from that document and cited to the page and table it appears in. Filed May 30, 2025.

$3.1M
$4.6M
FY23
FY24
SalaryBonusNon-equity incentiveStock awardsOption awards

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
PSU54,000$422,820—
RSU35,700$279,531—
Option448,634—$5.75
Option214,200—$14.36

Per the Outstanding Equity Awards at Fiscal Year-End table in Y-mAbs Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

10 Form 4 lines since the FY2024 proxy (filed May 30, 2025)
current to 2026-11-07 · updated nightly
DateTransactionPlanSharesPriceHeld after
2025-09-16Disposition to the issuer derivative—18,000—0
2025-09-16Disposition to the issuer derivative—52,650—0
2025-09-16Disposition to the issuer derivative—615,240—0
2025-09-16Disposition to the issuer derivative—214,200—0
2025-09-16Disposition to the issuer derivative—210,700—0
2025-09-16U—7,982$8.600
2025-09-16Disposition to the issuer—129,101—0
2025-09-16Disposition to the issuer derivative—18,000—0

The 8 most recent of 10 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Y-mAbs Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Michael Rossi · this pagePresident and Chief Executive Officer$4,557,590
Peter PfreundschuhTreasurer and Chief Financial Officer$2,504,717
Thomas GadFounder, Chief Business Officer and Vice Chairman of the Board of Directors$2,075,163

Board service

Y-mAbs Therapeutics board · FY2024

How this board is paid

Company policy: Y-mAbs Therapeutics pays directors a $50,000 cash retainer and $127,500 in RSUs/Options. As stated in Y-mAbs Therapeutics's FY2024 proxy.

The full Y-mAbs Therapeutics compensation record

free company brief

This page is one person within Y-mAbs Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Y-mAbs Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Y-mAbs Therapeutics's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Y-mAbs Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order YMAB

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Michael Rossi's compensation dossier